iCAD (NASDAQ:ICAD) Stock Passes Above Two Hundred Day Moving Average – Here’s What Happened

Shares of iCAD, Inc. (NASDAQ:ICAD) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.85 and traded as high as $3.54. iCAD shares last traded at $3.53, with a volume of 329,399 shares changing hands.

Analyst Ratings Changes

Separately, StockNews.com lowered iCAD from a “hold” rating to a “sell” rating in a research report on Wednesday.

iCAD Trading Up 1.7 %

The firm has a market capitalization of $93.69 million, a price-to-earnings ratio of -27.15 and a beta of 1.47. The company has a 50-day moving average of $2.27 and a 200-day moving average of $1.85.

Institutional Investors Weigh In On iCAD

Institutional investors and hedge funds have recently made changes to their positions in the company. Perritt Capital Management Inc increased its position in iCAD by 1.9% in the fourth quarter. Perritt Capital Management Inc now owns 189,100 shares of the technology company’s stock worth $346,000 after buying an additional 3,600 shares during the period. Geode Capital Management LLC increased its position in iCAD by 6.6% in the fourth quarter. Geode Capital Management LLC now owns 276,493 shares of the technology company’s stock worth $506,000 after buying an additional 17,059 shares during the period. PKS Advisory Services LLC acquired a new stake in iCAD in the fourth quarter worth $53,000. First Eagle Investment Management LLC increased its position in iCAD by 6.1% in the fourth quarter. First Eagle Investment Management LLC now owns 716,161 shares of the technology company’s stock worth $1,311,000 after buying an additional 41,000 shares during the period. Finally, Thompson Davis & CO. Inc. acquired a new stake in iCAD in the fourth quarter worth $31,000. 24.61% of the stock is owned by institutional investors and hedge funds.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.